Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach
The objective of this study was to rapidly identify ICI-IA patients in clinical data and assess associated immune-related adverse events (irAEs) and risk factors.MethodsWe conducted a retrospective study of the electronic health records (EHRs) of 89 patients who developed ICI-IA out of 2451 cancer patients who received ICI therapy at Northwestern University between March 2011 to January 2021. Logistic regression and random forest machine learning models were trained on all EHR diagnoses, labs, medications, and procedures to identify ICI-IA patients and EHR codes indicating ICI-IA. Multivariate logistic regression was then ...
Source: Frontiers in Immunology - March 15, 2024 Category: Allergy & Immunology Source Type: research
Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
CONCLUSIONS: High pre-treatment LIPI is suggested by our results to be a significant independent predictor of poor prognosis in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.PMID:38485656 | DOI:10.1093/jjco/hyae031 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 14, 2024 Category: Cancer & Oncology Authors: Shimpei Yamashita Shuzo Hamamoto Junya Furukawa Kazutoshi Fujita Masayuki Takahashi Makito Miyake Noriyuki Ito Hideto Iwamoto Yasuo Kohjimoto Isao Hara Source Type: research
GSE261551 Case Report: Molecular Profiling Facilitates the Diagnosis of a Challenging Case of Lung Cancer with Choriocarcinoma Features
We present a 35-year female with lung cancer with choriocarcinoma features. Her disease involved the right lower lung, brain, and thoracic lymph nodes. The pathology from brain metastasis was reported as “metastatic choriocarcinoma” (a germ cell tumor) by local pathologists. She initiated carboplatin and etoposide, a regimen for choriocarcinoma. Subsequently, her case was assessed by pathologists from an academic cancer center, who gave the diagnosis of “adenocarcinoma with aberrant expression of β-hCG” and finally pathologists at our hospital, who gave the diagnosis of “poorly differentiated carcinoma with cho...
Source: GEO: Gene Expression Omnibus - March 14, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report
We present two cases of mucosal melanoma, each with potential regional dissemination, who were treated with neoadjuvant immunotherapy with minimal toxicity. Both patients were closely monitored and achieved radiologic and pathologic complete responses. These patients were able to avoid radical surgery and related functional consequences. Both patients remain recurrence-free with protracted follow-up. The potential usefulness of neoadjuvant immunotherapy as an organ preservation strategy in mucosal melanoma deserves further evaluation in prospective clinical trials. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant
ConclusionWe describe nine patients with HCC outside Milan with inadequate response with liver-directed therapy, who achieved marked responses with CPIT, allowing for consideration of successful liver transplantation. Our case series supports the consideration of locoregional therapies and CPIT for downstaging to within transplant criteria. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - March 14, 2024 Category: Cancer & Oncology Source Type: research
Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors
ConclusionBoth ICI and BRAFi/MEKi carry a risk of cardiac dysfunction. However, without any underlying cardiac disease or severe cardiac dysfunction, their administration should not necessarily be excluded if careful follow-up is provided. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 11, 2024 Category: Cancer & Oncology Source Type: research
Corrigendum to “Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial” [Eur J Cancer 199 (2024) 113531]
The authors regret to notify a change to an author institution detail in this manuscript. Professor Marchetti requests to correct their institution information From: Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy - To: Istituto Dermopatico dell'Immacolata IDI IRCCS, Rome, Italy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Elena Simonetti, Federica Santangelo, Giovanni Amato, Alessia Covre, Roberto Camerini, Monica V Tags: Corrigendum Source Type: research
Immunotherapy of Human Melanoma: Past, Present, Future
Curr Med Chem. 2024 Mar 6. doi: 10.2174/0109298673283943240227104122. Online ahead of print.ABSTRACTImmunotherapy with immune checkpoint inhibitors (ICIs) is a promising therapeutic schedule in advanced solid cancers. In this review, clinical trials from highly reputable journals are interpreted for safety and efficacy evaluation of the common anti-programmed death-1 (PD-1) inhibitor nivolumab and/or the most known anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor ipilimumab in advanced melanoma. Current progress in the field of melanoma immunotherapy is the focus of this review. Solo nivolumab and combo ...
Source: Current Medicinal Chemistry - March 8, 2024 Category: Chemistry Authors: Keywan Mortezaee Jamal Majidpoor Source Type: research
Immunotherapy of Human Melanoma: Past, Present, Future
Curr Med Chem. 2024 Mar 6. doi: 10.2174/0109298673283943240227104122. Online ahead of print.ABSTRACTImmunotherapy with immune checkpoint inhibitors (ICIs) is a promising therapeutic schedule in advanced solid cancers. In this review, clinical trials from highly reputable journals are interpreted for safety and efficacy evaluation of the common anti-programmed death-1 (PD-1) inhibitor nivolumab and/or the most known anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor ipilimumab in advanced melanoma. Current progress in the field of melanoma immunotherapy is the focus of this review. Solo nivolumab and combo ...
Source: Current Medicinal Chemistry - March 8, 2024 Category: Chemistry Authors: Keywan Mortezaee Jamal Majidpoor Source Type: research
Immunotherapy of Human Melanoma: Past, Present, Future
Curr Med Chem. 2024 Mar 6. doi: 10.2174/0109298673283943240227104122. Online ahead of print.ABSTRACTImmunotherapy with immune checkpoint inhibitors (ICIs) is a promising therapeutic schedule in advanced solid cancers. In this review, clinical trials from highly reputable journals are interpreted for safety and efficacy evaluation of the common anti-programmed death-1 (PD-1) inhibitor nivolumab and/or the most known anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor ipilimumab in advanced melanoma. Current progress in the field of melanoma immunotherapy is the focus of this review. Solo nivolumab and combo ...
Source: Current Medicinal Chemistry - March 8, 2024 Category: Chemistry Authors: Keywan Mortezaee Jamal Majidpoor Source Type: research
Immunotherapy of Human Melanoma: Past, Present, Future
Curr Med Chem. 2024 Mar 6. doi: 10.2174/0109298673283943240227104122. Online ahead of print.ABSTRACTImmunotherapy with immune checkpoint inhibitors (ICIs) is a promising therapeutic schedule in advanced solid cancers. In this review, clinical trials from highly reputable journals are interpreted for safety and efficacy evaluation of the common anti-programmed death-1 (PD-1) inhibitor nivolumab and/or the most known anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor ipilimumab in advanced melanoma. Current progress in the field of melanoma immunotherapy is the focus of this review. Solo nivolumab and combo ...
Source: Current Medicinal Chemistry - March 8, 2024 Category: Chemistry Authors: Keywan Mortezaee Jamal Majidpoor Source Type: research
Two acute kidney injury episodes after ICI therapy: a case report
AbstractA 74-year-old Japanese male with lung squamous cell carcinoma received his first dose of immune checkpoint inhibitors (ICIs): ipilimumab and nivolumab. He developed acute kidney injury (AKI) and was admitted to our department. We diagnosed kidney immune-related adverse effects (irAE), and a kidney biopsy revealed acute tubulointerstitial nephritis. We started oral prednisolone (PSL) and his AKI immediately improved. The patient maintained stable findings after PSL was tapered off. However, seven months after the ICI administration, he developed rapid progressive glomerular nephritis and was admitted to our departme...
Source: CEN Case Reports - March 7, 2024 Category: Urology & Nephrology Source Type: research
Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma
Intern Med. 2024 Mar 4. doi: 10.2169/internalmedicine.3115-23. Online ahead of print.ABSTRACTCombination therapy with ipilimumab and nivolumab is indicated for many types of cancers; however, several patients experience immune-related adverse events (irAEs). We herein report a case of cytokine release syndrome (CRS) in a 63-year-old woman with stage IV left clear cell renal cell carcinoma. Our patient developed CRS while taking prednisolone, 43 days after the start of ipilimumab and nivolumab administration. The patient was treated with steroid pulse therapy, which improved the symptoms of shock and respiratory failure. In...
Source: Internal Medicine - March 3, 2024 Category: Internal Medicine Authors: Kohei Yamamoto Shinsuke Shiotsu Misaki Sasakura Shunya Tanaka Shiho Goda Taisuke Tsuji Tatsuya Yuba Chieko Takumi Noriya Hiraoka Source Type: research
